Home › Biliary Tract Cancer › Illinois › Chicago
Biliary Tract Cancer clinical trials in Chicago, IL
4 studies for Biliary Tract Cancer are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
RecruitingPhase 1
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
RecruitingPhase 3
- Research Site, Chicago
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RecruitingPhase 1
- University of Illinois Cancer Center, Chicago
- University of Chicago Medicine, Chicago
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
RecruitingPhase 3
- Research Site, Chicago
- Research Site, Chicago
Biliary Tract Cancer trials in other cities
- Houston, TX19 studies
- Los Angeles, CA12 studies
- New York City, NY11 studies
- Nashville, TN11 studies
- Boston, MA11 studies
- Arlington, VA9 studies
- Baltimore, MD9 studies
- Dallas, TX8 studies
- Baldwin Park, CA7 studies
- San Antonio, TX7 studies
- Columbus, OH6 studies
- Washington, DC6 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.